Cagrisema (2.5+2.5)

Research Benefits

• Dual Incretin/Amylin Agonism: Combines cagrilintide (long-acting amylin analog) with semaglutide (GLP-1 agonist) for synergistic metabolic research
• Superior Weight Management: Phase III clinical data demonstrate greater body weight reduction compared to either component alone
• Appetite Regulation: Dual-pathway satiety signaling through both hindbrain amylin receptors and GLP-1 receptor-mediated pathways
• Glycemic Research: Investigated for improvements in insulin sensitivity and glycemic control beyond GLP-1 monotherapy
• Cardiometabolic Parameters: Research examines combined effects on lipid profiles, blood pressure, and inflammatory markers

Mechanism of Action

Cagrilintide (Long-Acting Amylin Analog)

• Activates amylin receptors (AMY1, AMY2, AMY3) in the area postrema and other hindbrain regions
• Slows gastric emptying and reduces glucagon secretion
• Promotes satiety through calcitonin receptor/RAMP complex signaling

Semaglutide (GLP-1 Receptor Agonist)

• Potent, selective GLP-1 receptor activation with enhanced albumin binding for extended half-life
• Stimulates glucose-dependent insulin secretion from pancreatic beta cells
• Reduces appetite through hypothalamic and brainstem GLP-1 receptor activation

The combination targets two distinct but complementary satiety pathways, producing additive effects on food intake reduction and metabolic regulation that exceed either agent alone.

Research Protocol

For research purposes only. Not for human consumption.

• Configuration: 2.5 mg cagrilintide + 2.5 mg semaglutide per vial
• Typical Research Dose: Titration protocols starting at lower doses with gradual escalation over 4-8 weeks
• Administration: Subcutaneous injection
• Frequency: Once weekly in most published research designs (both components have extended half-lives)

Reconstitution

• Reconstitute with bacteriostatic water
• Refrigerate at 2-8 °C; use within 30 days

Safety & Storage

• Lyophilized: -20 °C long-term; 2-8 °C up to 3 months
• Reconstituted: 2-8 °C; use within 30 days
• Protect from light

Research Considerations

• GI effects (nausea) are the most commonly reported finding in clinical research; dose titration mitigates onset
• Both components have extensive clinical trial safety data from Novo Nordisk's development program
• Monitor for potential pancreatitis risk markers as with all incretin-based compounds
• Contraindicated in research models with personal/family history of medullary thyroid carcinoma or MEN2
• For research use only

Frequently Asked Questions

• What is CagriSema?

  CagriSema is a combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), developed by Novo Nordisk. It targets two complementary metabolic pathways for enhanced weight management and glycemic control research.

• How does it compare to semaglutide alone?

  Phase III clinical data show CagriSema produces significantly greater weight reduction compared to semaglutide monotherapy, attributed to the additive satiety effects of dual amylin + GLP-1 receptor activation.

• Why once-weekly dosing?

  Both cagrilintide and semaglutide have been engineered with fatty acid modifications that enhance albumin binding, extending their half-lives to support once-weekly administration.

• What purity is this product?

  ≥99% purity verified by HPLC and mass spectrometry. Full COA provided.